CTS™ Immune Cell Serum Replacement (SR), 500 mL - Citations

CTS™ Immune Cell Serum Replacement (SR), 500 mL - Citations

View additional product information for CTS™ Immune Cell Serum Replacement (SR) - Citations (A4702903, A2596101, A4702901, A2596102, A4702902)

Showing 1 product Citations

Citations & References
Abstract
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.
AuthorsLu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, Feldman SA
JournalHum Gene Ther Methods
PubMed ID27897048
The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps, ... More